Table 2.
Efficacy of the HPV vaccine in women with CIN after 2 years of follow-up
| Variable | Post-injection condition of the lesion after 2 years of follow-up | Efficacy (%) | *P value | |||
|---|---|---|---|---|---|---|
| Normal | CIN 1 | CIN 2–3 | ||||
| N (%) | ||||||
| CIN 1 | Control (N = 35) | 16 (45.7) | 19 (54.3) | – | 54.9 | 0.02 |
| Two more doses of vaccination (N = 45) | 34 (75.6) | 11 (24.4) | – | |||
| CIN 2 | Controls (N = 35) | 14 (40) | – | 21 (60) | 63.3 | 0.01 |
| Two more doses of vaccination (N = 50) | 39 (78) | – | 11 (22) | |||
| CIN 3 | **Controls (N = 34) | 14 (41.2) | – | 20 (58.2) | 52.5 | 0.03 |
| ***Two more doses of vaccination (N = 43) | 31 (72.1) | – | 12 (27.9) | |||
Abbreviations: N Number; CIN Cervical intraepithelial neoplasia
* Data were analyzed with Fisher’s exact test
**One woman in the control group actually developed invasive cervical cancer
***All women with CIN 3 received 3 doses of the vaccination